FORT LAUDERDALE, FL — (Marketwired) — 10/28/14 — OmniComm Systems, Inc. (OTCQB: OMCM), a leading global provider of data management solutions for clinical trials, today announced a partnership with Business & Decision Life Sciences (BDLS), a contract research organization (CRO) and life sciences information technology consultancy headquartered in Brussels, Belgium. This partnership enhances OmniComm–s presence in key geographies as it continues to experience continued and sustained demand from within the European clinical market space for its electronic data capture (EDC) and clinical data management (CDM) cloud based technology. BDLS selected OmniComm–s CRO Preferred Program to provide sponsors with access to the most innovative EDC technology and enhance its CRO and IT service offerings. BDLS plans to deploy TrialMaster EDC across a number of European trials over the next two years.
“This strategic partnership with OmniComm came as a result of the growing demand for TrialMaster among our customers across Europe and North America,” said Stephen Bamford, Country Manager at BDLS. “We are confident that its ease of use and CDISC data standards functionality will meet our customers– needs for EDC at all phases of clinical trials and help them to successfully bring new medical solutions to market.”
For over twenty years BDLS has provided a range of global clinical development IT services, supporting clinical trials in the operational, data management, analytical, outcome research, and document writing areas and the implementation of technology-based, clinical applications and solutions tailored for the Life Sciences industry. As the company evolves its EDC strategy, BDLS has identified OmniComm Systems– EDC and CDM technology as mission critical to improving study efficiency, trial timelines, process complexity and facilitating adherence to CDISC standards. Moreover, OmniComm–s focus on interoperability enables easy integration with other best-in-class systems, comprehensively satisfying BDLS– clients unique requirements.
“Business & Decision Life Sciences has a long history of providing excellent IT solutions and services to sponsors and is viewed as a leader in driving clinical development technology initiatives,” said Kuno van der Post, senior vice president of business development, OmniComm Systems. “With this partnership, we look forward to working with Business & Decision to strengthen OmniComm–s presence in the European market and build on the growing momentum of our highly intuitive products and premium quality services.”
BDLS is part of the Business & Decision Group, an international consulting and Systems Integration Company founded in 1992 and listed on the Eurolist C exchange.
BDLS is specialized in the delivery of services and provision of solutions in the Life Sciences industry. With 20 years of experience, it supports its clients in the pharmaceutical, medical device, biotechnology, food and cosmetics industries.
Core skills include the provision of a range of expert CRO and consulting services (supporting clinical trials in the operational, data management, analytical, outcome research, and document writing area) and the implementation of technology-based, clinical applications and solutions tailored for the Life Sciences industry.
BDLS is headquartered in Brussels, Belgium and has a strong international presence in five countries in North America and Europe.
OmniComm Systems is a leading strategic software solutions provider to the life sciences industry. OmniComm Systems is dedicated to helping the world–s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms and academic medical centers to maximize the value of their clinical research investments. Through the use of our innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations– performance. OmniComm provides comprehensive solutions for clinical research with extensive global experience from over 4,000 clinical trials. For more information, visit .
Statements made by OmniComm Systems included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company–s ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company–s financial results can be found in the Company–s Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
You must be logged in to post a comment Login